Please use this identifier to cite or link to this item: https://doi.org/10.3389/fendo.2021.609110
Title: Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis
Authors: Wong, Chloe
Lee, Ming Hui 
Yaow, Clyve Yu Leon
Chin, Yip Han
Goh, Xin Lei
Ng, Cheng Han
Lim, Amanda Yuan Ling
Muthiah, Mark Dhinesh
Khoo, Chin Meng
Keywords: Science & Technology
Life Sciences & Biomedicine
Endocrinology & Metabolism
glucagon-like peptide-1 receptor agonist
non-alcoholic fatty liver disease
type 2 diabetes mellitus
GLP-1RA
meta-analysis
Issue Date: 9-Apr-2021
Publisher: FRONTIERS MEDIA SA
Citation: Wong, Chloe, Lee, Ming Hui, Yaow, Clyve Yu Leon, Chin, Yip Han, Goh, Xin Lei, Ng, Cheng Han, Lim, Amanda Yuan Ling, Muthiah, Mark Dhinesh, Khoo, Chin Meng (2021-04-09). Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis. FRONTIERS IN ENDOCRINOLOGY 12. ScholarBank@NUS Repository. https://doi.org/10.3389/fendo.2021.609110
Abstract: Objective: Non-alcoholic fatty liver disease is highly prevalent in patients with type 2 diabetes mellitus. Studies on glucagon-like peptide-1 receptor agonists for the treatment of non-alcoholic fatty liver disease have reported promising results. Despite this, there has been limited evidence of its efficacy in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus. This meta-analysis examined existing evidence on the efficacy of glucagon-like peptide-1 receptor agonists on the management of non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Methods: Medline, Embase and Cochrane Central Register of Controlled Trials (CENTRAL) were searched for articles discussing the efficacy of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Values of standardized mean differences (SMD) and risk ratio (RR) were determined for continuous outcomes and dichotomous outcomes respectively. Results: 8 studies involving 1,454 patients from 5 randomized controlled trials and 3 cohort studies were included in the analysis. Our analysis found significant improvements in hepatic fat content, liver biochemistry, body composition, glucose parameters, lipid parameters, insulin sensitivity and inflammatory markers following glucagon-like peptide-1 receptor agonist treatment. Glucagon-like peptide-1 receptor agonists significantly decreased hepatic fat content compared to metformin and insulin-based therapies. Glucagon-like peptide-1 receptor agonists also improved fibrosis markers, but this did not reach statistical significance. Conclusion: With a high prevalence of obesity and non-alcoholic fatty liver disease among patients with type 2 diabetes mellitus, glucagon-like peptide-1 receptor agonist treatment shows promise in improving both diabetes and non-alcoholic fatty liver disease phenotype.
Source Title: FRONTIERS IN ENDOCRINOLOGY
URI: https://scholarbank.nus.edu.sg/handle/10635/206120
ISSN: 16642392
DOI: 10.3389/fendo.2021.609110
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes A Meta-Analysis.pdf1.05 MBAdobe PDF

OPEN

PublishedView/Download

SCOPUSTM   
Citations

10
checked on May 14, 2022

Page view(s)

54
checked on May 12, 2022

Download(s)

1
checked on May 12, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.